Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.22
+0.05 (0.22%)
At close: Sep 11, 2026, 4:00 PM EDT
25.36
+0.14 (0.58%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Pacira BioSciences Employees
As of December 31, 2025, Pacira BioSciences had 829 total employees, including 825 full-time and 4 part-time employees. The number of employees increased by 39 or 4.94% compared to the previous year.
Employees
829
Change (1Y)
39
Growth (1Y)
4.94%
Revenue / Employee
$900,077
Profits / Employee
$17,657
Market Cap
1.01B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 829 | 39 | 4.94% | 825 | 4 |
| Dec 31, 2024 | 790 | 78 | 10.96% | 788 | 2 |
| Dec 31, 2023 | 712 | -3 | -0.42% | 711 | 1 |
| Dec 31, 2022 | 715 | 18 | 2.58% | 715 | 0 |
| Dec 31, 2021 | 697 | 73 | 11.70% | 697 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,461 |
| Phibro Animal Health | 2,605 |
| Amphastar Pharmaceuticals | 1,976 |
| ANI Pharmaceuticals | 970 |
| Cronos Group | 610 |
| Xeris Biopharma Holdings | 435 |
| Glass House Brands | 426 |
| Collegium Pharmaceutical | 423 |
PCRX News
- 3 days ago - Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’ - TheFly
- 3 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Pacira initiated with a Market Perform at Leerink - TheFly
- 26 days ago - Pacira reinstated with a Buy at Truist - TheFly
- 5 weeks ago - Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases - GlobeNewsWire
- 5 weeks ago - Pacira price target raised to $25 from $24 at RBC Capital - TheFly
- 5 weeks ago - Pacira BioSciences Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Pacira BioSciences Earnings release: Q2 2026 - Filings